Compound Detail
CHEMBL49429
LIXIVAPTAN 🧪 Phase III
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase III
Basic Information
| ChEMBL ID | CHEMBL49429 |
| Name | LIXIVAPTAN |
| Phase | Phase III |
| Structure Type | MOL |
| InChI Key | PPHTXRNHTVLQED-UHFFFAOYSA-N |
5
Targets
33
Activities
2
Assay Types
21
PK Parameters
20
Publications
9
Known Names
4
Indications
1
Mechanisms
Molecular Properties
473.9
MW (Da)
6.05
ALogP
3
HBA
1
HBD
54.3
PSA (Ų)
0.39
QED
1
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Vasopressin V2 receptor antagonist | ANTAGONIST | Vasopressin V2 receptor | ✓ | ✓ |
Indications
Hyponatremia Polycystic Kidney Diseases Polycystic Kidney, Autosomal Dominant Heart Failure
Activity Summary
IC50 28 meas. best 9.3
Ki 5 meas. best 8.64
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Vasopressin V2 receptor CHEMBL3766 | IC50 | 9.3 | 8.805 | 0.5 | 4 |
| Vasopressin V2 receptor CHEMBL1790 | IC50 | 9.0 | 8.4164 | 1.0 | 11 |
| Vasopressin V2 receptor CHEMBL1790 | Ki | 8.64 | 7.7767 | 2.3 | 3 |
| Vasopressin V1a receptor CHEMBL1889 | Ki | 7.36 | 6.29 | 44.0 | 2 |
| Vasopressin V1a receptor CHEMBL2868 | IC50 | 7.09 | 6.605 | 82.0 | 4 |
| Vasopressin V1a receptor CHEMBL1889 | IC50 | 6.91 | 6.755 | 124.0 | 8 |
| Oxytocin receptor CHEMBL2049 | IC50 | 6.29 | 6.29 | 519.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 2960.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 1540.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 1570.0 | ng.hr.mL-1 | Homo sapiens |
| AUC | 140.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 219.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1530.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1890.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 4700.0 | ng.hr.mL-1 | Canis lupus familiaris |
| AUC | 4870.0 | ng.hr.mL-1 | Canis lupus familiaris |
| Cmax | 922.06 | nM | Homo sapiens |
| Cmax | 192.01 | nM | Rattus norvegicus |
| Cmax | 713.17 | nM | Rattus norvegicus |
| Cmax | 1601.47 | nM | Canis lupus familiaris |
| T1/2 | 9.77 | hr | Homo sapiens |
| T1/2 | 1.3 | hr | Rattus norvegicus |
| T1/2 | 4.2 | hr | Rattus norvegicus |
| T1/2 | 8.8 | hr | Canis lupus familiaris |
| Tmax | 0.7 | hr | Homo sapiens |
| Tmax | 0.8 | hr | Rattus norvegicus |
| Tmax | 0.8 | hr | Rattus norvegicus |
| Tmax | 0.8 | hr | Canis lupus familiaris |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.6019/CHEMBL5058577 | U2OS | 304 |
| - | 10.6019/CHEMBL5724801 | U2OS | 304 |
| - | 10.6019/CHEMBL5058577 | Fibroblast | 304 |
| - | 10.6019/CHEMBL5724801 | HEK-293T | 304 |
| - | 10.6019/CHEMBL5058577 | HEK-293T | 304 |
| - | 10.6019/CHEMBL5724801 | Fibroblast | 304 |
| 9651149 | 10.1021/jm980179c | Rattus norvegicus | 24 |
| 22474055 | 10.1124/dmd.112.044933 | Rattus norvegicus | 10 |
| 22474055 | 10.1124/dmd.112.044933 | Homo sapiens | 7 |
| - | 10.6019/CHEMBL5058564 | Fibroblast | 6 |
| - | 10.6019/CHEMBL5058564 | U2OS | 6 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 6 |
| - | 10.6019/CHEMBL5209801 | Type-1 angiotensin II receptor | 5 |
| - | 10.6019/CHEMBL5209801 | C5a anaphylatoxin chemotactic receptor 1 | 5 |
| - | 10.6019/CHEMBL5209801 | Glucagon-like peptide 1 receptor | 5 |
| - | 10.6019/CHEMBL5209801 | Adhesion G-protein coupled receptor F1 | 5 |
| 22474055 | 10.1124/dmd.112.044933 | Canis familiaris | 5 |
| - | 10.6019/CHEMBL5209801 | Beta-2 adrenergic receptor | 5 |
| - | 10.6019/CHEMBL5209801 | Apelin receptor | 5 |
| - | 10.6019/CHEMBL5209801 | Alpha-2A adrenergic receptor | 5 |
Data from ChEMBL 36 via Core Engine